



Contacts:

Helixir Co.Ltd.

SBI Biotech Co. Ltd.

Media: Hyesung Kim

Media: Atsuko Toda

Phone number: +82-2-878-2930

Phone number: +81-3-5789-3200

<http://www.helixir.co.kr>

www.sbibiotech.jp

SBI BIOTECH ENTERS INTO A CONTRACT WITH HELIXIR IN KOREA TO
DEVELOP SARUNASHI (HARDY KIWIFRUIT) EXTRACT, PG102
IN JAPAN EXCLUSIVELY

TOKYO, JAPAN, and SEOUL, SOUTH KOREA, October 14, 2008 - SBI Biotech Co., Ltd, a subsidiary of SBI Holdings, Inc., and Helixir Co., Ltd., an R&D Bio-Venture company in Korea announced that they have entered into a contract to develop and sell Helixir's nutraceutical, Sarunashi (kind kiwifruit) extract, PG102 with anti-allergic effect in Japan exclusively.

Efficacy of PG102 was confirmed by using various allergic disease animal models, for example for atopic dermatitis, asthma, rhinitis, and food allergy. No serious side effects have been found. Furthermore, a human trial was performed in Korea and the effectiveness of PG102 in humans was confirmed by measuring the serum level of IgE. Development of PG102 as a nutraceutical product in the Japanese market is another example of SBI Biotech's plan to contribute to society through research and development of innovative pharmaceutical and nutraceutical products.

Helixir has not only PG102 but also other rich pipelines. SBI Biotech will cooperate with Helixir to develop, introduce and sell Helixir's pipeline products to the Japanese market.

About Sarunashi extract PG102

PG102 is an Extract of Sarunashi (Hardy kiwifruits, *Actinidia arguta*) that is a kind of edible kiwifruits. PG102 has anti-allergic and strong anti-inflammatory action.

PG102 is expected to be useful for therapy of allergic diseases such as atopic dermatitis, pollen allergy, the allergic rhinitis, the food allergies and asthma.

About Helixir Co., Ltd.

Helixir Co., Ltd. are a research and development company in South Korea, and owns innovative pharmaceutical and nutraceutical products by using South Korea traditional herbal medicines and novel cell biology technology. Helixir advances the clinical trial of various medicines and nutraceutical in South Korea, U.S, EU, and Japanese market. For more information on Helixir, please refer to the company's website at www.helixir.co.kr.

About SBI Biotech Co., Ltd.

SBI Biotech Co., Ltd, the drug subsidiary company of SBI Holdings, Inc. is conducting its business as the global bioventure company by assembling discovery pipelines from Japan, United States, China and Korea. SBI Biotech advances drug discovery and new therapy by utilizing the global network of SBI researchers, receiving investments from venture capital and by collaborating with pharmaceutical companies and university hospitals. For more information on SBI Biotech, please refer to the company's website at www.sbibiotech.jp .

#